2014
DOI: 10.1517/14656566.2015.983077
|View full text |Cite
|
Sign up to set email alerts
|

Clinical, economic and societal impact of antibiotic resistance

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
79
0
10

Year Published

2015
2015
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 113 publications
(91 citation statements)
references
References 16 publications
(13 reference statements)
2
79
0
10
Order By: Relevance
“…In order to cause infection, these pathogens produce a range of virulence factors which in turn, promote host tissue damage and contribute to bacterial evasion from the host’s immune response and their subsequent survival in the bloodstream (Bhatty et al, 2015; Thammavongsa et al, 2015; Theilacker et al, 2015). This scenario coupled with a diminished antibiotic pipeline has lead to serious social and economic complications and it has prompted the search of novel compounds and therapies to combat bacterial infections (Barriere, 2015). …”
Section: Introductionmentioning
confidence: 99%
“…In order to cause infection, these pathogens produce a range of virulence factors which in turn, promote host tissue damage and contribute to bacterial evasion from the host’s immune response and their subsequent survival in the bloodstream (Bhatty et al, 2015; Thammavongsa et al, 2015; Theilacker et al, 2015). This scenario coupled with a diminished antibiotic pipeline has lead to serious social and economic complications and it has prompted the search of novel compounds and therapies to combat bacterial infections (Barriere, 2015). …”
Section: Introductionmentioning
confidence: 99%
“…The development of antibiotic resistance will obviously impede treatment of several bacterial infections. It will also affect other elements of modern hospital care, e.g., cancer treatment, transplantations and advanced surgery, disciplines that are highly reliant on the use of antibiotics to defeat bacterial infections (Barriere 2015). …”
Section: Antibiotic Resistancementioning
confidence: 99%
“…Overlooked for many years due to associated nephro-and neurotoxicity (25,26), colistin is increasingly used to treat life-threatening infections (24) and as an inhaled therapy in CF to prevent establishment of infection by MDR bacteria (25). While resistance to colistin remains low (27), the emergence of colistin-resistant strains heralds fears of a postantibiotic era (28).…”
mentioning
confidence: 99%